Wave Life Sciences Pte. Ltd. (NASDAQ:WVE) had its price objective hoisted by investment analysts at Jefferies Group from $28.00 to $42.00 in a report released on Monday. The brokerage presently has a “buy” rating on the stock. Jefferies Group’s price objective suggests a potential upside of 10.82% from the stock’s current price.

WVE has been the topic of a number of other reports. JMP Securities reiterated a “buy” rating on shares of Wave Life Sciences Pte. in a report on Tuesday, August 16th. Leerink Swann reiterated an “outperform” rating and issued a $45.00 target price on shares of Wave Life Sciences Pte. in a report on Thursday, November 10th. Finally, Zacks Investment Research upgraded shares of Wave Life Sciences Pte. from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $33.60.

Shares of Wave Life Sciences Pte. (NASDAQ:WVE) opened at 37.90 on Monday. The company’s 50-day moving average is $31.96 and its 200-day moving average is $23.40. Wave Life Sciences Pte. has a 12 month low of $8.95 and a 12 month high of $38.50. The firm’s market cap is $889.70 million.

Wave Life Sciences Pte. (NASDAQ:WVE) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.14. On average, equities research analysts forecast that Wave Life Sciences Pte. will post ($2.29) earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in WVE. Perceptive Advisors LLC raised its stake in Wave Life Sciences Pte. by 196.9% in the second quarter. Perceptive Advisors LLC now owns 522,595 shares of the company’s stock worth $10,812,000 after buying an additional 346,595 shares in the last quarter. BlackRock Fund Advisors raised its stake in Wave Life Sciences Pte. by 5.6% in the third quarter. BlackRock Fund Advisors now owns 203,599 shares of the company’s stock worth $6,611,000 after buying an additional 10,835 shares in the last quarter. Vanguard Group Inc. raised its stake in Wave Life Sciences Pte. by 14.9% in the second quarter. Vanguard Group Inc. now owns 117,861 shares of the company’s stock worth $2,439,000 after buying an additional 15,295 shares in the last quarter. Northern Trust Corp raised its stake in Wave Life Sciences Pte. by 174.2% in the third quarter. Northern Trust Corp now owns 91,433 shares of the company’s stock worth $2,969,000 after buying an additional 58,088 shares in the last quarter. Finally, State Street Corp purchased a new stake in Wave Life Sciences Pte. during the second quarter worth about $1,752,000. Institutional investors and hedge funds own 61.15% of the company’s stock.

About Wave Life Sciences Pte.

WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

5 Day Chart for NASDAQ:WVE

Receive News & Stock Ratings for Wave Life Sciences Pte. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences Pte. Ltd. and related stocks with our FREE daily email newsletter.